Gynecologic oncology最新文献

{"title":"Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States.","authors":"Kathleen M McClain, Vimalanand S Prabhu, Srujitha Marupuru, Ke Meng, Vy Tran, Robert Orlowski, Robin Meng, Angela K Green, Vicky Makker","doi":"10.1016/j.ygyno.2026.08.009","DOIUrl":"https://doi.org/10.1016/j.ygyno.2026.08.009","url":null,"abstract":"<p><strong>Objective: </strong>Describe real-world outcomes among patients with dMMR/MSI-H advanced or recurrent endometrial cancer (EC) treated with first-line (1 L) pembrolizumab monotherapy or carboplatin-paclitaxel.</p><p><strong>Methods: </strong>This retrospective cohort study used the Flatiron Health Research Database (January 1, 2013-June 30, 2025). Adult patients with dMMR/MSI-H advanced or recurrent EC who initiated pembrolizumab monotherapy or carboplatin-paclitaxel as 1 L therapy on or after May 1, 2017, were included. Real-world time on treatment (rwTOT) and time to next treatment or death (rwTTNT) were estimated using Kaplan-Meier methods overall and by prior neoadjuvant/adjuvant platinum therapy.</p><p><strong>Results: </strong>Of the 228 patients included, 80 received pembrolizumab and 148 carboplatin-paclitaxel. Median age ranged from 65 to 70 years; most patients had endometrioid histology (86.3%) and recurrent disease (78.8%). Among patients with prior neoadjuvant/adjuvant platinum therapy n = 41, 75.6% (n = 31) received pembrolizumab and (n = 10) 24.4% received carboplatin-paclitaxel. Median rwTOT (months) was 9.1 (95% CI: 5.1-14.5) for pembrolizumab and 3.5 (95% CI: 3.4-3.5) for carboplatin-paclitaxel. Median rwTTNT was 16.6 (95% CI: 9.4-32.3) for pembrolizumab and 5.8 (95% CI: 5.4-6.2) for carboplatin-paclitaxel. Among patients with prior platinum therapy, rwTOT and rwTTNT were 12.2 (95% CI: 4.9-23.5) and 23.1 (95% CI: 7.2-NE) for pembrolizumab, and 3.1 (95% CI: 0.0-3.7) and 5.4 (95% CI: 1.9-15.2) for carboplatin-paclitaxel.</p><p><strong>Conclusions: </strong>These real-world findings suggest pembrolizumab may be an effective chemotherapy-free option for patients with dMMR/MSI-H advanced or recurrent EC. Confirmatory evidence from the ongoing KEYNOTE-C93 trial (NCT05173987) will help inform its efficacy in this setting.</p>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of serum glucagon-like peptide-1 (GLP-1) levels in endometrial cancer among obese women","authors":"Arzu Bostancı Durmuş,&nbsp;Gamze Sinem Yücel","doi":"10.1016/j.ygyno.2026.09.004","DOIUrl":"10.1016/j.ygyno.2026.09.004","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic value of serum glucagon-like peptide-1 (GLP-1) levels in obese women with different endometrial pathologies and its independent association with endometrial cancer.</div></div><div><h3>Methods</h3><div>This prospective cross-sectional study included 180 obese, non-diabetic women undergoing endometrial biopsy for abnormal uterine bleeding, categorized as endometrial polyp (<em>n</em> = 60), endometrial hyperplasia (<em>n</em> = 60), or endometrioid-type endometrial cancer (<em>n</em> = 60). Fasting serum GLP-1 levels were measured by enzyme-linked immunosorbent assay. Correlation, multivariable logistic regression, and receiver operating characteristic (ROC) analyses were performed.</div></div><div><h3>Results</h3><div>Serum GLP-1 levels were significantly lower across the three groups, with the lowest levels in endometrial cancer (14.6 ± 3.1, 11.2 ± 2.8, and 7.4 ± 2.1 pg/mL in the polyp, hyperplasia, and cancer groups, respectively; <em>p</em> &lt; 0.001). GLP-1 was negatively correlated with age (ρ = −0.309, <em>p</em> &lt; 0.001) and CRP (ρ = −0.293, <em>p</em> &lt; 0.001), while no significant correlations were observed with HbA1c, CA-125, WBC, neutrophil, platelet, or lymphocyte counts. In multivariable analysis, increasing age (adjusted OR 1.320, 95% CI 1.159–1.503; <em>p</em> &lt; 0.001) and lower GLP-1 levels (adjusted OR 0.744 per 1 pg/mL increase, 95% CI 0.636–0.871; <em>p</em> &lt; 0.001) remained independently associated with endometrial cancer after adjustment for BMI, HbA1c, hypertension, CRP, and CA-125. GLP-1 demonstrated high discriminatory performance (AUC 0.94, 95% CI 0.90–0.97), with an optimal cutoff of 9.12 pg/mL, 86.0% sensitivity, and 91.6% specificity.</div></div><div><h3>Conclusion</h3><div>Lower serum GLP-1 levels were independently associated with endometrial cancer in obese, non-diabetic women. Although GLP-1 was negatively correlated with CRP, its association with endometrial cancer remained significant after adjustment for CRP and other relevant factors, suggesting that this relationship may not be explained solely by systemic inflammation. Serum GLP-1 may have potential as an adjunctive biomarker for risk stratification; however, prospective multicenter validation is required.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"213 ","pages":"Pages 102-108"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149074485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study","authors":"Robert M. Wenham,&nbsp;Isabelle Ray-Coquard,&nbsp;Rebecca Kristeleit,&nbsp;Daniela Matei,&nbsp;Sharad Ghamande,&nbsp;Ana Oaknin,&nbsp;Jonathan S. Berek,&nbsp;J. Alejandro Perez-Fidalgo,&nbsp;Pau Guillén Sentís,&nbsp;Eva M. Guerra Alia,&nbsp;June Hou,&nbsp;Phillipe Follana,&nbsp;Lauriane Eberst,&nbsp;Andrew Clamp,&nbsp;Jean-Sebastien Frenel,&nbsp;Patricia Roxburgh,&nbsp;Robert H. Jones,&nbsp;Patricia Pautier,&nbsp;Amanda L. Jackson,&nbsp;Deborah K. Armstrong,&nbsp;Vicky Makker","doi":"10.1016/j.ygyno.2026.08.023","DOIUrl":"10.1016/j.ygyno.2026.08.023","url":null,"abstract":"<div><h3>Background</h3><div>In this phase 1/2 study, we assessed the safety/antitumor activity of farletuzumab ecteribulin (FZEC), a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in patients with pretreated solid tumors.</div></div><div><h3>Methods</h3><div>Patients aged ≥18 years with measurable disease (per RECIST v1.1) were included. Patients with ovarian cancer (OC), endometrial cancer (EC), TNBC, and NSCLC were included in Dose-Escalation (0.9 mg/kg and 1.2 mg/kg IV Q3W). Patients with OC/EC were included for Dose-Confirmation (25 mg/m² and 33 mg/m² IV Q3W) and Dose-Optimization-part-A (8 mg/m² D1/D8/D15, 12 mg/m² D1/D8; 25 mg/m² D1 + steroid IV Q3W).</div></div><div><h3>Results</h3><div>Eighty-nine patients were enrolled (median age: 67.0 years); most (88.7%) patients with OC and 50.0% patients with EC received ≥2 previous anticancer regimens. In Dose-Escalation (<em>n</em> = 25), interstitial lung disease (ILD)/pneumonitis occurred in 40% of patients. The dosing methodology was amended to body surface area-based dosing in subsequent study parts as an ILD/pneumonitis-mitigation strategy. In Dose-Confirmation (<em>n</em> = 24), 33.3% of patients experienced ILD/pneumonitis. In the 25 mg/m² cohort, all ILD/pneumonitis events were grade-1/2. Evaluation of the 33 mg/m² dose was discontinued due to observed ILD/pneumonitis. Dose equivalents of 25 mg/m² were further evaluated in Dose-Optimization-part-A, with steroids/fractionated dosing (to mitigate ILD/pneumonitis). Patients receiving 8 mg/m² D1/D8/D15 experienced no ILD/pneumonitis and achieved more responses versus other regimens, but the subgroup sizes were small. With steroids, incidence of ILD/pneumonitis was similar, but onset appeared delayed.</div></div><div><h3>Conclusions</h3><div>Fractionated doses of FZEC reduced the risk of ILD/pneumonitis and showed preliminary antitumor activity. Dose-Optimization-part-B will test additional FZEC fractionated doses (alone and in combination with lenvatinib) and concomitant steroid use.</div><div>Clinical Trial Registration #: <span><span>NCT04300556</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"213 ","pages":"Pages 109-119"},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"It is not only about who collects the sample, it is about how it is processed and analyzed.","authors":"Eef van den Borst, Ardashel Latsuzbaia, Marc Arbyn, Alex Vorsters, Davy Vanden Broeck, Wiebren Tjalma, Severien Van Keer","doi":"10.1016/j.ygyno.2026.08.010","DOIUrl":"https://doi.org/10.1016/j.ygyno.2026.08.010","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond laboratory workflow: Specimen adequacy, methodological protocols, and real-world operational effectiveness in HPV self-sampling.","authors":"Ruhi Dixit, Ankita Chakrawal, Roli Purwar, Manoj Pandey","doi":"10.1016/j.ygyno.2026.09.012","DOIUrl":"https://doi.org/10.1016/j.ygyno.2026.09.012","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy complications in gynecologic oncologists – A call to action to do better","authors":"Brooke Sanders,&nbsp;Christine S. Walsh","doi":"10.1016/j.ygyno.2026.09.001","DOIUrl":"10.1016/j.ygyno.2026.09.001","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"212 ","pages":"Pages A1-A2"},"PeriodicalIF":4.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC","authors":"","doi":"10.1016/S0090-8258(26)02124-4","DOIUrl":"10.1016/S0090-8258(26)02124-4","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"212 ","pages":"Pages iv-vi"},"PeriodicalIF":4.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149004332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial","authors":"Matthew A. Powell,&nbsp;Henrik Roed,&nbsp;Lyndsay J. Willmott,&nbsp;David Cibula,&nbsp;Destin Black,&nbsp;Giorgio Valabrega,&nbsp;Sudarshan Sharma,&nbsp;Stefan Kommoss,&nbsp;Lisa M. Landrum,&nbsp;Ingrid Boere,&nbsp;Cara Mathews,&nbsp;Vladyslav Sukhin,&nbsp;Michael A. Gold,&nbsp;Caroline Lundgren,&nbsp;Sarah E. Gill,&nbsp;Lucy Gilbert,&nbsp;Ilana Cass,&nbsp;Mitchell I. Edelson,&nbsp;Joseph Buscema,&nbsp;Nicole S. Nevadunsky,&nbsp;Trine Nøttrup","doi":"10.1016/j.ygyno.2026.05.008","DOIUrl":"10.1016/j.ygyno.2026.05.008","url":null,"abstract":"<div><h3>Objective</h3><div>Dostarlimab+carboplatin-paclitaxel (CP) demonstrated significant improvement in progression-free survival (PFS) and clinically meaningful improvement in overall survival (OS) vs CP alone among patients with dMMR/MSI-H primary advanced/recurrent endometrial cancer (EC) in Part 1 of the randomized phase 3 RUBY trial (<span><span>NCT03981796</span><svg><path></path></svg></span>). We report updated efficacy and safety data with approximately 4 years of follow-up.</div></div><div><h3>Methods</h3><div>Patients were randomized 1:1 to receive dostarlimab+CP or placebo+CP followed by dostarlimab or placebo up to 3 years or until disease progression. Descriptive analyses of OS and PFS were conducted in the dMMR/MSI-H population (median follow-up, 55.6 months). Post hoc conditional survival analyses and a mixture cure model (MCM) fitted to PFS data to estimate the proportion of patients who had curative potential are presented to provide prognostic insights into long-term survival.</div></div><div><h3>Results</h3><div>Dostarlimab+CP demonstrated sustained OS and PFS benefits. Median PFS and OS were not reached with a 66% reduction in risk of death vs placebo+CP. PFS curve plateauing (only 4 progression events with additional 2.5 years follow-up since the previous PFS analysis at interim analysis 1) demonstrated durable disease control. Patients alive at the 1- and 2-year landmarks had &gt;80% probability of remaining alive an additional 3 and 2 years, respectively. At 4 years, the MCM analysis estimated a cure rate with dostarlimab of 54% (95% CI 35%–72%). No new safety signals were observed.</div></div><div><h3>Conclusions</h3><div>At 4 years, RUBY demonstrated sustained remission and long-term survival benefit, suggesting the potential for curative intent with dostarlimab+CP in patients with dMMR/MSI-H primary advanced or recurrent EC.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"212 ","pages":"Pages 207-217"},"PeriodicalIF":4.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC","authors":"","doi":"10.1016/S0090-8258(26)02088-3","DOIUrl":"10.1016/S0090-8258(26)02088-3","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"211 ","pages":"Pages iv-vii"},"PeriodicalIF":4.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148736291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A path to precision in endometrial cancer management: Moving past FIGO 2023","authors":"Jessica N. McAlpine,&nbsp;David Mutch","doi":"10.1016/j.ygyno.2026.07.022","DOIUrl":"10.1016/j.ygyno.2026.07.022","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"211 ","pages":"Pages A1-A2"},"PeriodicalIF":4.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}